Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors

Fig. 6

Disruption of cell cycle and DNA damage by ITC-6102RO. (A) Cell cycle distribution in H23 and JIMT-1 cells after treatment with Naked mAb, ITC-02-050 (free drug), or ITC-6102RO at 0.1 µM for 48 h. Propidium iodide (PI)-stained cells were analyzed using flow cytometry. (B) Cyclin expression changes in response to treatment with Naked mAb, ITC-02-050 (free drug), or ITC-6102RO. H23 and JIMT-1 cells were treated with Naked mAb, ITC-02-050, or ITC-6102RO at 0.1 µM for the indicated periods, and Western blotting was performed to detect expression changes of cyclins. (C) DNA damage effect induced by Naked mAb, ITC-02-050, or ITC-6102RO. H23 and JIMT-1 cells were treated with Naked mAb, ITC-02-050, or ITC-6102RO at 0.1 µM for the indicated periods, and Western blotting was conducted using γH2AX, p-Chk1, and Chk1 antibodies

Back to article page